Jonathan McNeill
Fortune : 3 M $ au 30/06/2026
Fortune : 3 M $ au 30/06/2026
Jonathan McNeill is President & Chief Operating Officer at Crescent Biopharma, Inc. since 2025.
Dr. McNeill is Partner at Forbion Capital Partners Management Holding since 2025.
Formerly, Dr. McNeill was Associate Director-Business Development at Editas Medicine, Inc. from 2015 to 2019.
Dr. McNeill was Vice President-Business Development at Dyne Therapeutics, Inc. from 2019 to 2021.
Dr. McNeill was President & Chief Operating Officer at Crescent Biopharma, Inc. (Old).
Education includes a doctorate and graduate degrees from the University of Pennsylvania Medical Center and the University of Pennsylvania in 2014, and an undergraduate degree from The University of North Carolina at Chapel Hill in 2007.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,5% | 22/06/2026 | 139 158 ( 0,5% ) | 3 M $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|
| Sociétés | Poste | Fin |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Corporate Officer/Principal | 03/09/2024 |
| EDITAS MEDICINE, INC. | Corporate Officer/Principal | 01/01/2019 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of North Carolina at Chapel Hill
The University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Editas Medicine, Inc.
Editas Medicine, Inc. BiotechnologyHealth Technology Manufactures gene editing medicines | Health Technology |
University of Pennsylvania Medical Center
University of Pennsylvania Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to treat muscle diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national